Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Jett

Thoracic Surgery (Cardiothoracic Vascular Surgery) Plano, TX Medical Doctor

NPI 1184690810 CMS profile 7825

4716 Alliance Blvd, Suite 310, Plano, TX 75093

Open in the dashboard

General payments

$277,153

512 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Jett of Plano, TX is reported in the CMS Open Payments database as having received $277,153 across 512 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,561 41
2024 General $7,096 32
2023 General $36,917 44
2022 General $23,908 51
2021 General $30,001 61
2020 General $74,093 116
2019 General $94,577 167

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Jett
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Gary Jett were reported at $10,561. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Gary Jett Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $94,577 $886 $178–$3,167 $163
2020 $74,093 $341 $108–$1,605 $114
2021 $30,001 $453 $125–$1,886 $132
2022 $23,908 $695 $180–$2,566 $149
2023 $36,917 $745 $205–$2,662 $160
2024 $7,096 $799 $214–$2,967 $164
2025 $10,561 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $238,555 395 payments
  2. Davol Inc. $21,505 94 payments
  3. CONMED Corporation $10,146 6 payments
  4. Atricure, Inc. $6,074 11 payments
  5. Becton, Dickinson and Company $874 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $152,232 57 payments
  2. Travel and Lodging $54,992 263 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,300 33 payments
  4. Consulting Fee $14,425 5 payments
  5. Food and Beverage $13,950 153 payments
  6. Gift $254 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $230,405 388 payments
  2. AIRSEAL $10,146 6 payments
  3. ARISTA $8,751 29 payments
  4. DA VINCI SP $8,150 7 payments
  5. ARISTA AH FlexiTip Surgery $6,960 30 payments
  6. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $5,230 6 payments
  7. ARISTA AH FLEXITIP BD Interventional Surgery $2,792 10 payments
  8. Progel Applicator Spray Tips Surgery $2,564 16 payments
  9. Progel Applicator Spray Tips BD Interventional Surgery $543 4 payments
  10. AtriCure cryoICE cryoSPHERE Cryoablation System $476 1 payment
  11. Other $1,323 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Prescriptions dispensed, refills included

Drug cost

$11,620

Paid at the pharmacy, in all

Branded share of claims

100%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 15 $11,620

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record